Background: Hidradenitis suppurativa (HS) is a difficult to manage disease. Randomized controlled trials with anti-TNF-α biologics have been conducted and in most studies disease activity was reduced. However, the mechanism of action in HS skin is so far unknown.
Objectives: To assess whether anti-TNF-α treatment affects in situ cytokine production and frequency of inflammatory cell populations in HS lesional skin.
Methods: Nine HS patients, participating in a larger placebo-controlled, double-blind phase IIb clinical trial on the efficacy and safety of adalimumab in patients with moderate to severe HS (M10-467), were randomized and ...
Adalimumab (anti-TNF-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study is a post from: Skincare
Adalimumab (anti-TNF-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study via BuzzBlazer.com
No comments:
Post a Comment